source
- Merck’s Moderna-partnered vaccine success clears view of post-Keytruda futureInvestors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.BioSpace · 1h ago↗ source
- Merck and Moderna report success in late-stage trial of personalized mRNA cancer vaccineMerck and Moderna announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a randomized late-stage trial, marking the first demonstration that such an approach can be…